Korsana Biosciences

About Korsana Biosciences

Korsana Biosciences is dedicated to building best-in-class therapeutics to reduce the burden of neurodegenerative diseases, with a focus on delivering safe and efficacious drugs to the central nervous system (CNS) and overcoming challenges like the blood-brain barrier (BBB). Their mission is to provide better solutions for patients and caregivers, starting with Alzheimer's disease.

Products & Services

THETA™ Platform:A novel blood-brain barrier (BBB)-penetrant shuttle platform designed to enhance CNS exposure of investigational therapies, overcoming limitations of earlier technologies.

KRSA-028:A lead program featuring a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer's disease.

Specialties

Neurodegenerative disease therapeutics Blood-brain barrier (BBB) penetration technology Alzheimer's disease treatment Precision-engineered therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 175000000 MR: - FA: 175 million FAN: 175000000	D: 2026-02-18 FD: 2026-02-18	8 investors

Series A Latest

2026-02-18

$175.0M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jonathan Violin

Chief Executive Officer

K

Kyle Breidenstine

SVP, Finance

M

Maddy Zeylikman

General Counsel

A

Andrew Gottesdiener

Director

T

Tomas Kiselak

Chairman

N

Nilesh Kumar

Director

View 7 more team members with Pro

Unlock Full Team Directory

Recent News